Fresenius Medical Care North America’s renal therapies group announced today that it launched the Speedswap for the NxStage System One with NxView.
Speedswap, a new option for the NxStage System One with NxView, enables the changing of a flow-compromised dialysis filter without replacing the entire cartridge.
According to a news release, Fresenius designed the new Speedswap system to help reduce therapy downtime, ease nursing workloads and lower treatment costs in acute care settings by improving the filter change through the use of a pre-attached, yet detachable, filter that allows for the replacement without replacing a cartridge.
“This introduction of Speedswap aims to both improve the quality of dialysis treatment in the critical care setting and make our technology even easier to use by the care team,” said Joe Turk, president of the Renal Therapies Group at Fresenius Medical Care North America. “This product is another example of how we are always working to introduce innovations that improve our NxStage System One and ensure it remains the first and best choice of all hospitals for continuous therapy.”
Fresenius said the system brings two products to the market for use with NxStage System One with NxView in the form of Cartridge Express with Speedswap and the Speedswap Express Kit. The Speedswap system includes shipping connectors for maintaining sterility and integrity of valves, which enable the user to disconnect the pre-attached filter.
Speedswap also offers a line restrictor for pressure adjustment within venous and arterial lines, a “Safe2” rotator connector to prevent accidental disconnect and improve handling, pressure-oscillating diaphragm (POD) technology for eliminating the blood-air interface and needleless vales for minimizing the occurrence of air in the circuit.
The NxStage System One with NxView features a volumetric fluid balancing system that allows for fluid accuracy without the need for scales.
“The simplified filter exchange should help make our life-sustaining therapy even easier to provide in an often busy critical care setting,” said Dr. Mike Anger, CMO for FMCNA’s Renal Therapies Group. “We also hope to improve patient outcomes by reducing the time necessary to change dialysis filters which should minimize interruption to continuous kidney replacement therapy.”
